Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis

Overview

The main objective is to assess the efficacy of a new formulation containing chondroitin sulfate and glucosamine sulfate (CS+GS) compared with placebo in patients with primary osteoarthritis of the knee.

Full Title of Study: “Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondroitin Sulfate and Glucosamine Sulfate in Combination Versus Placebo in Patients With Osteoarthritis of the Knee”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 2014

Detailed Description

The purpose of this study is to determine whether a new combination of chondroitin sulfate and glucosamine sulfate administered once a day is superior to placebo in the treatment of patients with moderate to severe knee osteoarthritis. Eligible patients will be randomized 1:1 and the treatments will be administered for 24 weeks. Clinical efficacy at the end of treatment will be evaluated. Safety will be evaluated through adverse events recoding during the study period.

Interventions

  • Drug: CS+SG
    • Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
  • Drug: Placebo
    • Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.

Arms, Groups and Cohorts

  • Experimental: CS+SG
    • Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks
  • Placebo Comparator: Placebo
    • Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Change in Pain According to VAS (0-100 mm)
    • Time Frame: 24 weeks
    • VAS=The visual analogue scale is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, the patients specify their condition by indicating a position along a continuous line between two end-points. In our case a 0-100 mm line was used to define the degree of pain. The change between baseline and each evaluation visit (week 4, week 12 and week 24) was calculated to evaluate the efficacy of the treatments (a negative number represents a decrease in pain).

Participating in This Clinical Trial

Inclusion Criteria

  • Patient >= 45 years . – Primary OA of the knee according to ACR criteria. – OA radiological grade II-III according to Kellgren and Lawrence. – Patients with moderate-severe pain. Exclusion Criteria:

  • Patients with clinical significant trauma or surgery in the target knee. – Concurrent arthritic disease (antecedents and/or current signs) that could confound or interfere with the evaluation of pain efficacy such as chondrocalcinosis, Paget's disease of the ipsilateral limb to the target knee, rheumatoid arthritis, aseptic osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis, Wilson's disease, osteochondromatosis, seronegative spondyloarthropathy, mixed connective tissue disease, collagen vascular disease, psoriasis, inflammatory bowel disease or fibromyalgia. – Pain in other parts of the body greater than the knee pain that could interfere with the evaluation. – Subjects with any active acute or chronic infections requiring antimicrobial therapy, or serious viral (e.g., hepatitis, herpes zoster, HIV positivity) or fungal infections. – Clinical diagnosis established of uncontrolled diabetes mellitus. – Patients with asthma. – History of hypersensitivity to the active drugs or any excipients of the formulations.

Gender Eligibility: All

Minimum Age: 45 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Tedec-Meiji Farma, S.A.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • FJ Blanco, M.D., Principal Investigator, Complejo Hospitalario Universitario La Coruña

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.